Abstract:A diverse group of RNA viruses have the ability to gain access to the central nervous system (CNS) and cause severe neurological disease. Current treatment for people with this type of infection is generally limited to supportive care. To address the need for reliable antivirals, we utilized a strategy of lethal mutagenesis to limit virus replication. We evaluated ribavirin (RBV), favipiravir (FAV) and N 4 -hydroxycytidine (NHC) against La Crosse virus (LACV), which is one of the most common causes of pediatric arboviral encephalitis cases in North America and serves as a model for viral CNS invasion during acute infection. NHC was approximately 3 to 170 times more potent than RBV or FAV in neuronal cells. Oral administration of molnupiravir (MOV), the prodrug of NHC, decreased neurological disease development (assessed as limb paralysis, ataxia and weakness, repeated seizures, or death) by 31% (4 mice survived out of 13) when treatment was started on the day of infection. MOV also reduced disease by 23% when virus was administered intranasally (IN). NHC and MOV produced less fit viruses by incorporating predominantly G to A or C to U mutations. Furthermore, NHC also inhibited virus production of two other orthobunyaviruses, Jamestown Canyon virus and Cache Valley virus. Collectively, these studies indicate that NHC/MOV has therapeutic potential to inhibit viral replication and subsequent neurological disease caused by orthobunyaviruses and potentially as a generalizable strategy for treating acute viral encephalitis. Mutagenic ribonucleosides can be viewed as broadly acting antivirals against RNA viruses. These viruses have small genomes of essential genes and thus are susceptible to enhanced mutation rates as an antiviral strategy. Here we show that the mutagenic ribonucleoside N 4 -hydroxycytidine (NHC) and its prodrug molnupiravir are active against the negative strand bunyavirus La Crosse Virus. Loss of viral infectivity was proportional to the density of mutations induced by NHC. Using a mouse model, we showed that oral administration of molnupiravir attenuated encephalitis caused by La Crosse virus and resulted in reduced virus titers and less fit virus in the brain. This treatment approach should be widely applicable to acute RNA virus diseases, especially those with high morbidity and an absence of other treatment options.

Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir

N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody

In Vitro Mitochondrial Toxicity Of Metacavir, A New Nucleoside Reverse Transcriptase Inhibitor For Treatment Of Hepatitis B Virus

Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry

Molnupiravir: Mechanism of action, clinical, and translational science

Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity

Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment

Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.

β-d-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus

Two short approaches to the COVID-19 drug beta-D-N4- hydroxycytidine and its prodrug molnupiravir

Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids

Molnupiravir, a ribonucleoside antiviral prodrug against SARS-CoV-2, alters the voltage-gated sodium current and causes adverse events

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.

Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis

Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19

Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases

N 4 -Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses

In Vivo Assessment of Mitochondrial Toxicity of Metacavir in Rhesus Monkeys after Three Months of Intravenous Administration

Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations